Intriguingly, the diversity in OS was significant in the PD-L1+ subgroup of patients, suggesting that the potential clinical utility of PD-L1 expression.[6,7] In BC, quite a few studies have currently suggested that positive PD-L1 BC was related with poorer OS,[8–10] but other studies could not verify this finding.[11,12] However, according to provided results, this eye on the value of PD-L1 in BC still did not reach a consensus that further validation is urgently awaited. Here, CD274 is linked to breast cancer.